Priya Singhal - 16 Feb 2024 Form 4 Insider Report for BIOGEN INC. (BIIB)

Role
Head of Development
Signature
/s/ Wendell Taylor, attorney-in-fact for Priya Singhal
Issuer symbol
BIIB
Transactions as of
16 Feb 2024
Net transactions value
-$126,450
Form type
4
Filing time
21 Feb 2024, 21:27:09 UTC
Previous filing
13 Feb 2024
Next filing
26 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIIB Common Stock Options Exercise $0 +819 +18% $0.000000 5,335 16 Feb 2024 Direct
transaction BIIB Common Stock Tax liability $64,629 -295 -5.5% $219.08 5,040 16 Feb 2024 Direct
transaction BIIB Common Stock Options Exercise $0 +389 +7.7% $0.000000 5,429 16 Feb 2024 Direct
transaction BIIB Common Stock Tax liability $37,901 -173 -3.2% $219.08 5,256 16 Feb 2024 Direct
transaction BIIB Common Stock Sale $23,921 -108 -2.1% $221.49 5,148 16 Feb 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIIB Performance Stock Unit Options Exercise $0 -819 -100% $0.000000* 0 16 Feb 2024 Common Stock 819 $0.000000 Direct
transaction BIIB Restricted Stock Unit Options Exercise $0 -389 -45% $0.000000 485 16 Feb 2024 Common Stock 389 $0.000000 Direct F1
transaction BIIB Restricted Stock Unit Other $0 -485 -100% $0.000000* 0 16 Feb 2024 Common Stock 485 $0.000000 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This award was granted to the reporting person on February 18, 2021. The number of Restricted Stock Units ("RSUs") reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
F2 This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.